[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:sanfilippo-syndrome":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":40,"states":41},"Sanfilippo Syndrome",5,[7,15,21,27,34],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06333041","Study of Cannabidiol in Sanfilippo Syndrome",[11],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:16:00.194860Z","2026-05-05T02:43:29.729287Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT02716246","Phase I\u002FII\u002FIII Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH",[11],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:28.741288Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT06614894","An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III",[11],"2026-08-26T02:16:27.227548Z","2026-04-29T02:57:57.067665Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":32,"content_modified":33},"NCT02254863","UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells",[31],"Phase 1","2026-08-26T02:17:07.954622Z","2026-05-05T02:43:26.720663Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT03333200","Longitudinal Study of Neurodegenerative Disorders",[],"2026-08-26T02:18:51.009190Z","2026-05-13T02:55:06.121889Z",[],[]]